New treatment options for panic disorder: clinical trials from 2000 to 2010.

Abstract:

INTRODUCTION:Panic disorder (PD) is a prevalent psychiatric disorder characterized by unexpected and recurrent panic attacks. PD patients present significant psychosocial impairment and a high risk of psychiatric comorbidities and suicide. PD should be treated effectively as soon as the symptoms emerge because the longer these patients remain without treatment, the worse the prognosis will be. AREAS COVERED:The authors carried out a systematic review of the literature regarding the pharmacological treatment of PD in the last 10 years. Only open studies, placebo-controlled studies or comparative clinical trials were selected. EXPERT OPINION:Compounds with reported effectiveness in the treatment of PD included tricyclic antidepressants, benzodiazepines, serotonin selective reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs) and other drugs. SSRIs and SNRIs are the first-line compounds in the treatment of PD. These drugs were better tolerated than tricyclics and benzodiazepines as they had a low risk of dependence and overdosing complications. The serotonergic, noradrenergic and GABAergic pathways play a major role in the fear network and in the physiopathology of PD. A better understanding of the role of these neurotransmitter systems in PD will allow the development of more effective drugs for this psychiatric condition.

authors

Freire RC,Hallak JE,Crippa JA,Nardi AE

doi

10.1517/14656566.2011.562200

subject

Has Abstract

pub_date

2011-06-01 00:00:00

pages

1419-28

issue

9

eissn

1465-6566

issn

1744-7666

journal_volume

12

pub_type

杂志文章,评审
  • Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline.

    abstract::Sertraline (Zoloft, Pfizer Inc.) is a selective serotonin re-uptake inhibitor (SSRI) which has been approved by the US FDA for the treatment of premenstrual dysphoric disorder (PMDD). PMDD is a severe form of premenstrual syndrome (PMS) which affects at least 5 - 8% of women of reproductive age. It is characterised by...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.11.2065

    authors: Halbreich U,Kahn LS

    更新日期:2003-11-01 00:00:00

  • Cost-effectiveness of widespread screening for Chlamydia trachomatis.

    abstract::Screening for sexually transmitted diseases is included in routine health care for several infectious agents in many western European countries. Current considerations on extensions of these programs include widespread screening strategies for Chlamydia trachomatis. In women, C. trachomatis infection may lead to seque...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.10.1443

    authors: Postma MJ,Welte R,Morré SA

    更新日期:2002-10-01 00:00:00

  • Treatment options for esophageal cancer.

    abstract::There is considerable controversy over the level of evidence from randomized trials underpinning management decisions for patients presenting with localized cancer of the esophagus and esophago-gastric junction. There is also an optimism that new drugs and new approaches, including response prediction based on sequent...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560802560237

    authors: Murphy TJ,Ravi N,Reynolds JV

    更新日期:2008-12-01 00:00:00

  • Current treatment options and strategies for myelodysplastic syndromes.

    abstract:BACKGROUND:The myelodysplastic syndromes (MDS) are a group of heterogeneous disorders characterized by ineffective hematopoiesis. A number of scoring systems have been developed but they are of limited value in guiding individual patient treatment decisions. OBJECTIVE:We have presented the benefits and limitations of ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.10.1667

    authors: Srinivasan S,Schiffer CA

    更新日期:2008-07-01 00:00:00

  • Radiocontrast-induced nephropathy and percutaneous coronary intervention: a review of preventive measures.

    abstract::Injectable and absorbable contrast media for the use in radiology, all of which contains iodine as an essential component, has been, and continues to be, one of the main sources of agents which cause hospital-acquired renal failure. Although numerous methods have been explored to prevent renal contrast damage, radioco...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.5.639

    authors: Mintz EP,Gruberg L

    更新日期:2003-05-01 00:00:00

  • VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.

    abstract::Angiotensin-converting enzyme inhibitors (ACE-Is) are an evidence-based treatment for patients who after myocardial infarction (MI) present with either heart failure (HF) or left ventricular systolic dysfunction, or both. An alternative could be a more complete inhibition of the renin-angiotensin system through the bl...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1517/14656566.6.3.507

    authors: Maggioni AP,Fabbri G

    更新日期:2005-03-01 00:00:00

  • Palliative treatment of unresectable metastatic colorectal cancer.

    abstract:IMPORTANCE OF THE FIELD:Treatment options for metastatic colorectal cancer (mCRC) patients have rapidly increased in the past years, but 50 - 70% of mCRC patients are still unlikely to undergo radical resection of metastases and are candidates for palliative therapy only. AREAS COVERED IN THIS REVIEW:Oxaliplatin and i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903427997

    authors: Fornaro L,Masi G,Loupakis F,Vasile E,Falcone A

    更新日期:2010-01-01 00:00:00

  • Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.

    abstract:INTRODUCTION:Epilepsy is a serious and common chronic neurological disease with an urgent need for novel treatment options, because 30% of all epilepsy patients do not respond to currently available drugs. Retigabine/Ezogabine (RTG) is a third-generation antiepileptic drug (AED) with a novel mechanism of action. It enh...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.706278

    authors: Orhan G,Wuttke TV,Nies AT,Schwab M,Lerche H

    更新日期:2012-08-01 00:00:00

  • Sustained release oral fampridine in the treatment of multiple sclerosis.

    abstract:BACKGROUND:Fampridine-SR is under submission as the first drug to be FDA approved with an indication specifically for multiple sclerosis symptoms. Compounded forms of the active agent of Fampridine-SR (4-aminopyridine) have been used in clinical practice for many years. Clinical trials have now been completed that demo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903075994

    authors: Kachuck NJ

    更新日期:2009-08-01 00:00:00

  • Systemic retinoids in chemoprevention of non-melanoma skin cancer.

    abstract:BACKGROUND:The incidence of non-melanoma skin cancer is increasing worldwide. Systemic retinoids are useful for the chemoprophylaxis of non-melanoma skin cancers. Retinoids have pleiotropic effects, but their exact cancer chemopreventive mechanism is still not clear. OBJECTIVE:The aim of this study was to review publi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.8.1363

    authors: Lens M,Medenica L

    更新日期:2008-06-01 00:00:00

  • The management of dermatomyositis: current treatment options.

    abstract::Dermatomyositis is traditionally classified as one of the idiopathic inflammatory myopathies. The traditional approach to the management of patients with dermatomyositis focuses predominantly on end points related to the systemic manifestations of this disorder, especially proximal muscle weakness resulting from myosi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.5.1083

    authors: Sontheimer RD

    更新日期:2004-05-01 00:00:00

  • Acute promyelocytic leukemia: what are the treatment options?

    abstract:IMPORTANCE OF THE FIELD:Acute promyelocytic leukemia (APL) represents a paradigm of therapeutic success in clinical hematology. Since the introduction of all-trans-retinoic-acid in the early 1980s, complete remission rates exceed 90% and the cure rate is > 70%. Notwithstanding, various questions concerning the manageme...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903505115

    authors: Ferrara F

    更新日期:2010-03-01 00:00:00

  • Outpatient management of chronic heart failure.

    abstract:INTRODUCTION:Heart failure (HF) treatment attracts a share of intensive research because of its poor HF prognosis. In the past decades, the prognosis of HF has improved considerably, mainly as a consequence of the progress that has been made in the pharmacological management of HF. AREAS COVERED:This article reviews t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.978286

    authors: Kaldara E,Sanoudou D,Adamopoulos S,Nanas JN

    更新日期:2015-01-01 00:00:00

  • Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.

    abstract:INTRODUCTION:actinic keratosis is a premalignant disease with a high incidence and is a strong predictor for the development of squamous cell carcinoma. Various treatment options have been established over recent years, including topical treatment with imiquimod, 5-fluorouracil, diclofenac or photodynamic therapy, cryo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.549128

    authors: Quist SR,Gollnick HP

    更新日期:2011-02-01 00:00:00

  • Evolving treatment strategies for chronic refractory angina.

    abstract::Chronic refractory angina is a term used to describe patients who, despite optimal medical therapy, have both angina and objective evidence of ischaemia. It is estimated that 5-15% of the 12 million patients with chronic angina in the US meet the criteria for having refractory angina. This review focuses on the follow...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.3.259

    authors: Yang EH,Barsness GW

    更新日期:2006-02-01 00:00:00

  • Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.

    abstract:INTRODUCTION:Glioblastoma, the most common malignant brain tumor, exhibits a poor prognosis with little therapeutic progress in the last decade. Novel treatment strategies beyond the established standard of care with temozolomide-based radiotherapy are urgently needed. AREAS COVERED:We reviewed the literature on gliob...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1176146

    authors: Seystahl K,Gramatzki D,Roth P,Weller M

    更新日期:2016-06-01 00:00:00

  • Alprazolam extended-release in panic disorder.

    abstract::Alprazolam-XR is an extended-release formulation of alprazolam designed to deliver sustained therapeutic concentrations for 24 h after once-daily dosing. Plasma concentrations gradually decline as the time for the next dose approaches, but still remain above therapeutic minimum levels. The anti-panic efficacy of alpra...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 临床试验,杂志文章

    doi:10.1517/14656566.5.7.1599

    authors: Rickels K

    更新日期:2004-07-01 00:00:00

  • New antiviral agents for the treatment of hepatitis C: ABT-450.

    abstract:INTRODUCTION:Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from stu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.889116

    authors: Carrion AF,Gutierrez J,Martin P

    更新日期:2014-04-01 00:00:00

  • Comparative evaluation of efficacy and safety of cefotaxime-sulbactam with amoxicillin-clavulanic acid in children with lower respiratory tract infections.

    abstract:OBJECTIVE:Beta-lactamase producing bacteria present a major problem in treating lower respiratory tract infections. The objective of this study was to evaluate efficacy and safety of cefotaxime-sulbactam combination versus amoxicillin-clavulanic acid injection as an alternative therapeutic option for treatment of lower...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1517/14656566.9.16.2751

    authors: Pareek A,Kulkarni M,Daga S,Deshpande A,Chandurkar N

    更新日期:2008-11-01 00:00:00

  • Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.

    abstract:BACKGROUND:Chronic hyperglycemia has an adverse influence on beta-cell function, which is known as 'glucotoxicity'. Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower the blood glucose concentration by enhancing urinary glucose excretion. This study was performed to clarify the influence of the SGLT2 inhibitor ipr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 临床试验,杂志文章

    doi:10.1080/14656566.2016.1261110

    authors: Nagai Y,Ohta A,Sada Y,Kato H,Tanaka Y

    更新日期:2017-01-01 00:00:00

  • Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer.

    abstract:INTRODUCTION:Breast cancer (BC) remains the most frequently diagnosed cancer and the most common cause of cancer death among women of all races worldwide. Over 80% of BC cases are hormone receptor (HR)-positive, comprised of luminal A and luminal B per molecular subtypes, imposing an urgent need to fully understand the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2018.1429407

    authors: Duso BA,Trapani D,Viale G,Criscitiello C,D'Amico P,Belli C,Mazzarella L,Locatelli M,Minchella I,Curigliano G

    更新日期:2018-02-01 00:00:00

  • Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia.

    abstract:INTRODUCTION:Treating acute myeloid leukemia (AML) in older adults remains daunting. The unique biology often renders conventional chemotherapies less effective. Accurately predicting the toxicities of treatment is another unresolved challenge. Treatment planning thus requires a good knowledge of the current trial data...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1465562

    authors: Michaelis LC,Klepin HD,Walter RB

    更新日期:2018-06-01 00:00:00

  • Review of vorapaxar for the prevention of atherothrombotic events.

    abstract:INTRODUCTION:Atherosclerosis is frequently caused by clot blockage of the coronary or peripheral arteries, and may lead to myocardial infarction (MI) or peripheral arterial disease (PAD). Despite advancements in management of atherosclerosis, mortality and ischemic rates remain high. Vorapaxar is a protease activated r...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1099629

    authors: Wang A

    更新日期:2015-01-01 00:00:00

  • Treatment strategies for acute pulmonary embolism.

    abstract:BACKGROUND:Acute pulmonary embolism (PE) is a life-threatening condition that has been treated with anticoagulation for almost 50 years. OBJECTIVES:To review the current treatment options for PE and discuss recently published new features. METHODS:We reviewed literature involving the treatment strategies for venous t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902911470

    authors: Blondon M,Bounameaux H,Righini M

    更新日期:2009-05-01 00:00:00

  • Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development.

    abstract::Antiplatelet therapy is the cornerstone of treatment for patients who present with acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI). Clopidogrel, in combination with aspirin, is associated with improvement in long-term clinical outcomes in these patients and is currently the antiplatel...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.16.2893

    authors: Angiolillo DJ,Suryadevara S,Capranzano P,Bass TA

    更新日期:2008-11-01 00:00:00

  • The therapeutic management of differentiated thyroid cancer.

    abstract:BACKGROUND:The management of thyroid cancer is difficult because the tumors comprise a wide range of biologic behaviors, from small papillary thyroid microcarcinomas that pose little or no threat to survival for the patient, to anaplastic thyroid cancers that are arguably the most lethal tumor. Although it may be diffi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.15.2627

    authors: Sipos JA,Mazzaferri EL

    更新日期:2008-10-01 00:00:00

  • The optimal pharmacological formula for percutaneous coronary intervention.

    abstract:INTRODUCTION:Adjunctive pharmacotherapy is of key importance in determining the outcomes of percutaneous coronary intervention (PCI). In parallel, there has been an increasing body of evidence indicating that the aggressive management of coronary risk factors and changes in lifestyle behavior yield additional positive ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.546345

    authors: Capodanno D,Tamburino C,Dangas G

    更新日期:2011-05-01 00:00:00

  • Antimicrobial treatment of anaerobic infections.

    abstract:INTRODUCTION:Anaerobes are the most predominant components of normal human skin and mucous membrane bacterial flora and are, therefore, a common cause of endogenous bacterial infections. Because of their fastidious nature, they are difficult to isolate from infectious sites and are often overlooked. Anaerobic infection...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.576672

    authors: Brook I

    更新日期:2011-08-01 00:00:00

  • Pharmacotherapy of Paget's disease of bone.

    abstract:INTRODUCTION:Paget's disease of the bone is a common condition in some populations, affecting almost 10% of older adults in western Europe. Though frequently asymptomatic, it can sometimes result in severe disabilities. Timely intervention is now able to arrest disease progression in the majority of patients. AREAS CO...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.662486

    authors: Reid IR

    更新日期:2012-04-01 00:00:00

  • Drug interactions in the management of HIV infection.

    abstract::The availability of antiretroviral therapy has significantly reduced the morbidity and mortality of HIV infection. In addition, improved treatment of opportunistic infections and comorbidities common to patients with HIV is further prolonging the lives of patients. Improvement in the treatment of HIV has led to a sign...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.2.233

    authors: Robertson SM,Penzak SR,Pau AK

    更新日期:2005-02-01 00:00:00